Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 20;43(3):436-442.
doi: 10.12122/j.issn.1673-4254.2023.03.14.

[Comparison of therapeutic effect of metformin hydrochloride/vildagliptin and liraglutide on type 2 diabetes mellitus in obese patients]

[Article in Chinese]
B Zhou  1 , J Li  1 , C Fang  1 , Y Huang  1 , G Sang  1 , S Tao  1 , C He  2
Affiliations

[Comparison of therapeutic effect of metformin hydrochloride/vildagliptin and liraglutide on type 2 diabetes mellitus in obese patients]

[Article in Chinese]
B Zhou et al. Nan Fang Yi Ke Da Xue Xue Bao. .

Abstract
in English, Chinese

Objective: To evaluate the therapeutic effects of two therapeutic strategies based on metformin hydrochloride/vildagliptin and liraglutide on type 2 diabetes mellitus (T2DM) in obese patients.

Methods: We retrospectively collected the clinical data of 107 obese patients (BMI>25 kg/m2) with T2DM treated in Second Affiliated Hospital of Wannan Medical College (Wuhu, China) during 2019-2021, including 53 patients treated continuously with metformin hydrochloride/vildagliptin and 54 with liraglutide for 3 months. The changes in BMI, waist circumference, fasting blood glucose (FBG), postprandial blood glucose, HbA1C, fasting C-peptide, postprandial C-peptide, fasting insulin and postprandial insulin of the patients after treatment were compared between the two groups.

Results: In both of the groups, the patients all showed significant reductions of BMI, waist circumference, FBG, postprandial blood glucose and HbA1C (all P < 0.05) with improved fasting and postprandial C-peptide levels after the treatments (P < 0.05). The two treatment regimens showed comparable blood glucoselowering effects, but liraglutide produced better effect in reducing waist circumference (P < 0.01). Neither of two regimens obviously affected insulin level of the patients (P>0.05).

Conclusion: Both metformin hydrochloride/vildagliptin and liraglutide have good therapeutic effects on T2DM in obese patients and can achieve good blood glucose and weight control, but liraglutide has a better effect for weight control.

目的: 评价基于二甲双胍/维格列汀和利拉鲁肽的两种治疗方案对肥胖合并2型糖尿病患者（BMI>25 kg/m2）的临床疗效。

方法: 回顾性分析2019~2022年皖南地区107例肥胖合并2型糖尿病患者，根据所选患者初发肥胖合并2型糖尿病，将患者分为二甲双胍/维格列汀治疗组（n=53）和利拉鲁肽治疗组（n=54），持续治疗3个月。比较两组患者治疗前后的BMI、腹围、空腹血糖、餐后2 h血糖、糖化血红蛋白、空腹C肽、餐后2 hC肽、空腹胰岛素及餐后2 h胰岛素，观察治疗前后各项指标的变化。

结果: 107例皖南地区肥胖合并2型糖尿病患者中，二甲双胍/维格列汀组和利拉鲁肽组患者治疗前后的BMI（P < 0.05）、腹围（P < 0.05）、空腹血糖（P < 0.05）、餐后2 h血糖（P < 0.05）以及糖化血红蛋白（P < 0.05）均较前下降，空腹C肽及餐后2 hC肽较前恢复（P < 0.05）。对比两组治疗结果，血糖下降水平疗效相当，但利拉鲁肽组的腹围减少疗效更优（P < 0.01），两组治疗方案对患者的胰岛素水平影响并不显著（P>0.05）。

结论: 二甲双胍/维格列汀和利拉鲁肽作为新型降糖药物，对于肥胖合并2型糖尿病具有很好疗效，可以控制血糖、减轻体质量，但利拉鲁肽对患者体质量的控制效果相对更佳。

Keywords: liraglutide; metformin hydrochloride/vildagliptin; obesity; type 2 diabetes mellitus.

PubMed Disclaimer

Figures

图 1
图 1
二甲双胍维格列汀组BMI、腹围、空腹血糖及餐后C肽对糖化变化的相关性 Correlations of the changes in BMI, waist circumference, FBG and 2h CP with those of HbA1C in metformin/vildagliptin group.
图 2
图 2
利拉鲁肽组空腹血糖及餐后血糖对糖化变化的相关性 Correlations of the changes in BMI, waist circumference, FBG and 2h CP with those of HbA1C in liraglutide group.
See this image and copyright information in PMC

References

    1. Zhu RR, Zhou S, Xia L, et al. Incidence, Morbidity and years Lived With Disability due to Type 2 Diabetes Mellitus in 204 Countries and Territories: trends From 1990 to 2019. Front Endocrinol (Lausanne) 2022;13:905538. doi: 10.3389/fendo.2022.905538. - DOI - PMC - PubMed
    1. Su BB, Wang YR, Dong YH, et al. Trends in diabetes mortality in urban and rural China, 1987-2019:a joinpoint regression analysis. Front Endocrinol. 2022;12:777654. doi: 10.3389/fendo.2021.777654. - DOI - PMC - PubMed
    1. 中华医学会糖尿病学分会、国家基层糖尿病防治管理办公室 国家基层糖尿病防治管理指南(2022) 中华内科杂志. 2022;61(3):249. doi: 10.3760/cma.j.cn112138-20220120-000063. - DOI
    1. Zhang N, Du SM, Ma GS. Current lifestyle factors that increase risk of T2DM in China. Eur J Clin Nutr. 2017;71(7):832–8. doi: 10.1038/ejcn.2017.41. - DOI - PubMed
    1. Huang YM, Lin YK, Lee WJ, et al. Long-term outcomes of metabolic surgery in overweight and obese patients with type 2 diabetes in Asia. Diabetes Obes Metab. 2021;23(3):742–53. doi: 10.1111/dom.14279. - DOI - PubMed

Publication types

LinkOut - more resources